HDAC9 and ovarian cancer: Since the patient and the PDTO did not respond to the conventional chemotherapies for ovarian cancer, we assessed the antitumoral effect of innovative treatments, olaparib (a PARP inhibitor) and belinostat (a HDAC inhibitor), in the two PDTO models, O and XO.